Selexis offers comprehensive and rapid solutions for the development of stable, high yield mammalian cell lines used in recombinant protein manufacturing.
Based on the Selexis SUREtechnology Platform™ and world-class expertise, Selexis SURE Cell line development™ Services significantly reduces the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (e.g. monoclonal antibodies, growth factors, enzymes).
The development of high-yield production cell lines begins with the cloning of target genes into the SUREtech Vectors™ containing Selexis Genetic Elements™ (SGEs). These target gene-containing vectors are transfected either into the Selexis SURE CHO-M Cell line™ or another fully documented cell line provided by the client using the SUREfection™ procedure. From the stable transfectant population, and using up to two limiting dilution steps, Selexis selects for high expressing populations with favorable growth characteristics. A secondary limiting dilution step (single cell dilution) can be carried out, if necessary, to generate more clonal populations with even higher protein expression levels, SUREclones™.
Single site integration in the
host cell genome reduces the risk of endogenous gene disruption for unmatched stability and grams per liter productivities.
Selexis Facebook Page
Selexis LinkedIn Profile
Selexis Twitter Feed
Selexis YouTube channel
Your thoughts and questions are very important to us. Please feel free to email or call us directly.
EUROPE AND REST OF WORLD
+41 22 308 9360
+1 415 738 4813